More data indicated that the ATM inhibitor KU55933 remarkably increased the sensitivity of ovarian, cervical, and endometrial cancer cell line models to ionizing radiation therapy, without regard to P53 status, but failed to improve the tumor-killing effect of platinum-based drugs [61]. Here, TP53 is linked to endometrial cancer.